8-K filed Aug 28, 2026 at 17:25 ET
Spero Therapeutics entered into a new at-the-market (ATM) equity offering agreement with Jefferies LLC for up to $100M in common stock, filed concurrently with a $300M universal shelf registration statement (S-3). The company also terminated its prior $75M Cantor Fitzgerald ATM facility, under which it had sold no shares in FY2025 or FY2024. The new ATM is 1.4x the company's $70M market cap, representing massive potential dilution for a clinical-stage biotech with no approved products or near-term revenue prospects, and the shelf registration was filed just 16 days after a 10-Q showing a $70M market cap, signaling a distressed capital raise to fund preclinical development of SP001.